Published in Ann Pharmacother on January 01, 1992
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother (1993) 1.88
Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother (1998) 1.00
Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother (1996) 0.87
Crystal-induced acute kidney injury due to ciprofloxacin. J Nephropathol (2015) 0.82
Influence of renal failure on intestinal clearance of ciprofloxacin in rats. Antimicrob Agents Chemother (1999) 0.77
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
On the Interpretation of Multi-Hit Survival Curves. Proc Natl Acad Sci U S A (1949) 5.96
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother (1994) 3.73
Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ (1990) 3.25
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet (1979) 2.71
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet (1995) 2.66
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med (1989) 2.56
Bile acid transformations by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand (1967) 2.33
Role for dual individualization with cefmenoxime. Am J Med (1984) 2.29
Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother (1995) 2.29
Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci (1984) 2.20
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother (1998) 2.19
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther (1989) 2.08
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) (1991) 1.89
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother (1993) 1.88
In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother (1990) 1.83
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
Proliferation of human lymphocytes in culture. Nature (1966) 1.76
A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) (2007) 1.75
Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother (1989) 1.74
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis (1998) 1.71
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
A test for the practical evaluation of male fertility by acridine orange (AO) fluorescence. Fertil Steril (1984) 1.68
Weight history, glucose intolerance, and insulin levels in middle-aged Swedish men. Am J Epidemiol (1998) 1.66
A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol (1999) 1.59
Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother (1989) 1.59
Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther (1978) 1.59
Rapid destructive osteoarthritis: clinical, radiographic, and pathologic features. Radiology (1992) 1.56
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci (1979) 1.56
The mutational spectrum in Waardenburg syndrome. Hum Mol Genet (1995) 1.55
Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health Syst Pharm (1996) 1.53
Liquid-chromatographic determination of ciprofloxacin in serum and urine. Clin Chem (1985) 1.52
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother (1991) 1.52
Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother (1978) 1.51
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Parameters in 7-alpha-dehydroxylation of bile acids by anaerobic lactobacilli. Acta Pathol Microbiol Scand (1968) 1.50
A randomized study of the use of a customized immobilization system in the treatment of prostate cancer with conformal radiotherapy. Radiother Oncol (2000) 1.49
Gentamicin tissue accumulation and nephrotoxic reactions. JAMA (1978) 1.49
Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther (1977) 1.48
Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer (2002) 1.45
Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli. Antimicrob Agents Chemother (1988) 1.44
Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis (1992) 1.43
Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules. Aliment Pharmacol Ther (2012) 1.43
Predicting normal tissue injury in radiation therapy. Int J Radiat Oncol Biol Phys (1991) 1.43
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents (2000) 1.43
Using intact nerve to bridge peripheral nerve defects: an alternative to the use of nerve grafts. J Hand Surg Am (2001) 1.42
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother (1997) 1.42
Alteration of theophylline clearance and half-life by cimetidine in normal volunteers. Ann Intern Med (1981) 1.41
Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm (1999) 1.41
Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med (1991) 1.40
Is supplementation with elemental diet feasible in patients undergoing pelvic radiotherapy? Clin Nutr (2005) 1.39
Exonic STK11 deletions are not a rare cause of Peutz-Jeghers syndrome. J Med Genet (2006) 1.39
Microwave life-detection systems for searching human subjects under earthquake rubble or behind barrier. IEEE Trans Biomed Eng (2000) 1.39
Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother (1990) 1.38
Isolated fecal microorganisms capable of 7-alpha-dehydroxylating bile acids. J Exp Med (1966) 1.36
Myositis ossificans with atypical clinical, radiographic, or pathologic findings: a review of 23 cases. Skeletal Radiol (1992) 1.34
Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J Antimicrob Chemother (1987) 1.33
Determination of bile acid conversion potencies of intestinal bacteria by screening in vitro and subsequent establishment in germfree rats. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 1.32
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer (1995) 1.31
Oral hydralazine therapy for chronic refractory heart failure. Circulation (1976) 1.30
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother (1994) 1.30
Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest (1986) 1.29
Distended left renal vein: CT/sonographic normal variant. AJR Am J Roentgenol (1980) 1.28
The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol (1988) 1.28
Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother (1981) 1.27
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer (1999) 1.27
Excretion of 3beta-hydroxy-5-cholenoic and 3a-hydroxy-5a-cholanoic acids in urine of infants with biliary atresia. FEBS Lett (1971) 1.26
Osteonecrosis of the distal pole of the carpal scaphoid following fracture--a rare complication. Skeletal Radiol (1983) 1.24
Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol (1997) 1.24
Selection against chromosome aberrations in human lymphocytes. Nature (1967) 1.23
Chemotherapy for primary gastric lymphoma: does in-patient observation prevent complications? Clin Oncol (R Coll Radiol) (2004) 1.23
Methicillin distribution in serum and extravascular fluid and its relevance to normal and damaged heart valves. Antimicrob Agents Chemother (1981) 1.22
Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother (1979) 1.21
Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med (1991) 1.19
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.19
Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions. Antimicrob Agents Chemother (1980) 1.19
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol (2008) 1.18
Bile acids and pancreatic enzymes during absorption in the newborn. Acta Paediatr Scand (1972) 1.17
Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. J Antimicrob Chemother (1984) 1.15
Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer (2005) 1.15
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer (1998) 1.15
Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest (1978) 1.14
The induction of micronuclei in human lymphocytes by low doses of radiation. Int J Radiat Biol Relat Stud Phys Chem Med (1987) 1.14
Intracapsular and paraarticular chondromas. Clin Orthop Relat Res (1994) 1.14
Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection (2004) 1.13
Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr (1980) 1.13
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm (2000) 1.12
Are we discussing SUDEP?--A retrospective case note analysis. Seizure (2012) 1.11
Radial head-capitellum view in elbow trauma: clinical application and radiographic-anatomic correlation. AJR Am J Roentgenol (1984) 1.11
Radiation stimulated incorporation of thymidine into the DNA of human lymphocytes. Nature (1968) 1.09
Gross hematuria: a complication of intrapelvic cement intrusion in total hip replacement. AJR Am J Roentgenol (1978) 1.09